CliffBio
biologic

Darzalex Faspro

daratumumab and hyaluronidase-fihj

Loss of exclusivityMay 2032projected — 12-year biologic exclusivity estimate
CompanyJanssen Biotech →See this company's full patent-cliff portfolio

Drug detail

Brand nameDarzalex Faspro
Active ingredientdaratumumab and hyaluronidase-fihj
Strength1800MG/15ML; 30,000UNITS/15ML (120MG/2,000UNITS/ML)
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalMay 2020
Marketing statusRx

More from Janssen Biotech

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.